AR066048A1 - Metodos y composiciones para contribuir al tratamiento de canceres - Google Patents
Metodos y composiciones para contribuir al tratamiento de canceresInfo
- Publication number
- AR066048A1 AR066048A1 ARP080101522A ARP080101522A AR066048A1 AR 066048 A1 AR066048 A1 AR 066048A1 AR P080101522 A ARP080101522 A AR P080101522A AR P080101522 A ARP080101522 A AR P080101522A AR 066048 A1 AR066048 A1 AR 066048A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- compositions
- contribute
- cancer treatment
- interferon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos y composiciones para contribuir al tratamiento de cánceres, especialmente tumores ováricos. Los métodos y composiciones utilizan un agonista de endotelina B (ETB) para mejorar la administracion y la eficacia resultante del agente(s)quimioterapéutico. Reivindicacion 5: El método de acuerdo con la reivindicacion 1, en donde dicho agonista de ETB se selecciona del grupo formado por ET-1, ET-2, ET-3, BQ3020, IRL1620 (N-suc-[Glu9, Ala11, 15]ET-1 (8-21)), sarafotoxina 56c, [Ala1,3, 11,15]ET-1, y combinaciones de ellos. Reivindicacion 6: El método de acuerdo con la reivindicacion 1, en donde dicho agente quimioterapéutico se selecciona del grupo formado por adriamicina, camptotecina, carboplatina, cisplatina,ciclofosfamida, daunorubicina, alfa interferon, beta interferon, gamma interferon, interleucina 2, irinotecan, docetaxel, paclitaxel, topotecan, 5-fluorouracil y combinaciones de ellas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91177307P | 2007-04-13 | 2007-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066048A1 true AR066048A1 (es) | 2009-07-22 |
Family
ID=39521878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101522A AR066048A1 (es) | 2007-04-13 | 2008-04-11 | Metodos y composiciones para contribuir al tratamiento de canceres |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2144607B1 (es) |
JP (1) | JP5503528B2 (es) |
KR (1) | KR20100016392A (es) |
CN (1) | CN101686960A (es) |
AR (1) | AR066048A1 (es) |
BR (1) | BRPI0810215A2 (es) |
CA (1) | CA2683890C (es) |
DK (1) | DK2144607T3 (es) |
ES (1) | ES2453295T3 (es) |
HK (1) | HK1140145A1 (es) |
IL (1) | IL201502A (es) |
MX (1) | MX2009011041A (es) |
RU (1) | RU2009141845A (es) |
TW (1) | TWI439266B (es) |
WO (1) | WO2008127996A1 (es) |
ZA (1) | ZA200907083B (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508086A (ja) * | 2002-10-24 | 2006-03-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 固形腫瘍を予防および治療するための方法および組成物 |
WO2006091767A2 (en) * | 2005-02-22 | 2006-08-31 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
-
2008
- 2008-04-10 BR BRPI0810215-5A2A patent/BRPI0810215A2/pt not_active IP Right Cessation
- 2008-04-10 EP EP08733184.9A patent/EP2144607B1/en active Active
- 2008-04-10 JP JP2010503210A patent/JP5503528B2/ja active Active
- 2008-04-10 CN CN200880020158A patent/CN101686960A/zh active Pending
- 2008-04-10 DK DK08733184.9T patent/DK2144607T3/da active
- 2008-04-10 CA CA2683890A patent/CA2683890C/en active Active
- 2008-04-10 MX MX2009011041A patent/MX2009011041A/es not_active Application Discontinuation
- 2008-04-10 WO PCT/US2008/059949 patent/WO2008127996A1/en active Application Filing
- 2008-04-10 RU RU2009141845/15A patent/RU2009141845A/ru not_active Application Discontinuation
- 2008-04-10 ES ES08733184.9T patent/ES2453295T3/es active Active
- 2008-04-10 KR KR1020097023427A patent/KR20100016392A/ko not_active Application Discontinuation
- 2008-04-11 AR ARP080101522A patent/AR066048A1/es not_active Application Discontinuation
- 2008-04-14 TW TW097113439A patent/TWI439266B/zh active
-
2009
- 2009-10-12 ZA ZA2009/07083A patent/ZA200907083B/en unknown
- 2009-10-13 IL IL201502A patent/IL201502A/en active IP Right Grant
-
2010
- 2010-07-13 HK HK10106780.9A patent/HK1140145A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008240300A1 (en) | 2008-10-23 |
EP2144607A1 (en) | 2010-01-20 |
BRPI0810215A2 (pt) | 2014-10-21 |
IL201502A0 (en) | 2010-05-31 |
TW200904404A (en) | 2009-02-01 |
WO2008127996A1 (en) | 2008-10-23 |
KR20100016392A (ko) | 2010-02-12 |
MX2009011041A (es) | 2009-11-19 |
EP2144607B1 (en) | 2014-01-08 |
JP2010523697A (ja) | 2010-07-15 |
JP5503528B2 (ja) | 2014-05-28 |
IL201502A (en) | 2017-01-31 |
TWI439266B (zh) | 2014-06-01 |
DK2144607T3 (da) | 2014-04-07 |
HK1140145A1 (en) | 2010-10-08 |
CA2683890C (en) | 2020-01-07 |
ES2453295T3 (es) | 2014-04-07 |
ZA200907083B (en) | 2011-01-26 |
CN101686960A (zh) | 2010-03-31 |
RU2009141845A (ru) | 2011-05-20 |
CA2683890A1 (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Sargassum fusiforme polysaccharides inhibit VEGF-A-related angiogenesis and proliferation of lung cancer in vitro and in vivo | |
Fazio et al. | Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view | |
Sun et al. | Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer | |
NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
RU2016132759A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
EA200801132A1 (ru) | Новые улучшенные композиции для лечения рака | |
AR062177A1 (es) | Composiciones y articulos de fabricacion para contribuir al tratamiento contra el cancer | |
AR049305A1 (es) | Método para tratar cancer resistente al platino con un anticuerpo her2 y un agente quimioterapéutico:gemcitabina | |
PE20090156A1 (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas | |
WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
Jiang et al. | Wnt/β-catenin signaling pathway in lung cancer stem cells is a potential target for the development of novel anticancer drugs | |
BR112012008325A2 (pt) | N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico | |
SG171583A1 (en) | Composition for the treatment of resistant cancers comprising oridonin | |
PH12021550836A1 (en) | Intratumor injection formulation | |
KR20220075450A (ko) | 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도 | |
WO2010151005A3 (ko) | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 | |
Hernandez-Unzueta et al. | Ocoxin oral solution exerts an antitumoral effect in pancreatic cancer and reduces the stromal-mediated chemoresistance | |
JP2009545609A5 (es) | ||
ECSP109970A (es) | Mediacion de citotoxicidad de celulas que evidencian | |
MY150135A (en) | Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs | |
Yu et al. | Herbal medicine Guan Chang Fu Fang enhances 5-fluorouracil cytotoxicity and affects drug‑associated genes in human colorectal carcinoma cells | |
BR112022020482A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfiri | |
AR066048A1 (es) | Metodos y composiciones para contribuir al tratamiento de canceres | |
RU2010140611A (ru) | Комбинированное применение производных холестанола |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
FB | Suspension of granting procedure |